We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Angle Plc | AGL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 16.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 16.00 | 16.00 | 16.00 | 16.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 03/2/2025 20:49 by vitec The BB's are littered with individuals that state they have no agenda, no shares in the company they write about and want to save foolish investors from destroying their capital. They spend a large part of their day posting messages telling people that they are right.The other side of the coin is that there are many shareholders that stay out of the limelight, do not post or post infrequently and understand their investment. It is true that AGL stands at 10% of its value post FDA but the story has now become compelling. For a massive Pharma company to acknowledge AGL and stand "shoulder to shoulder" states "we believe in the technology and we are going to commercialise it". This is not any old Pharma. They are world leaders in liquid biopsy. This is what I want as a shareholder. We are in bed with a company that can propel AGL to far greater heights. What we are seeing at the moment is just the start. Feb 6th will be very interesting and I think it will result in AGL getting a lot more awareness and enquiries. Exciting times. |
Posted at 01/2/2025 14:40 by washingmachine To the lierAGL RNS less than 2 weeks ago Anticipating near 13 million on hand cash. For serious unconvicted investors We await illuminas presentation next week , with AGLs karren miller being one of the key speakers. Let me give you a heads up fraudster In my very strong opinion Your employer the NHS are about to take this up !! Which in turn will bring in huge returns over time to AGL. The only problem been I very much doubt they will be able to stay independent. |
Posted at 30/1/2025 11:39 by yasx I suspect once more information is conveyed next week relating to this relationship market participants will sit up and take notice - for now this is presenting an opportunity for investors/traders to clamber aboard. |
Posted at 05/11/2024 17:44 by ohwhatfun So in reality the waiting for the deal has already happened. The talk of majors/ deals pending was bull, misleading investors, that is definitely not what they meant and AGL know it.I hope the person asking the question sold in disgust. That is definitely not what investors were expecting and waiting for. 39,000 samples tested last year compared to 14,000 in H1 this year, but trust in AGL all the headings but revenue will double v H1 in H2. So in reality going by the history, the odds are another warning will come to adjust the $3-$3.7m forecast for the year. The product is great, the interest in it so far has been poor. The smaller bio funding issues taking away bread and butter sampling for AGL took a big hit (reported as such by them). It can be seen in numbers, 39,000 samples 2023 just 14,000 H1 2024, worry not all is well!!!!, trust in AGL and their news, not random non invested posters that seem to be far more accurate than AGL. So sorry to say, no more deals this year, just a hope that contacts extend left but likely the revised revenue forecast missed, slipped, headwinds, next finance period, Ariston and on and on....., I'll wait for the wording. Hopefully for holders something will come regarding the extra/extended contracts, but I fear the worst, it's constant hype with little delivery. |
Posted at 31/10/2024 04:23 by bones698 I have this account and no other ,maybe look at my posting history . Now your just making up things to suit your narrative . You do realise most investors lose on aim around 80% and around 90% of shares lose investors money right . So tell me who has better odds of being right .just one article showing the risks ,funny how so many think they have picked the right one though |
Posted at 11/10/2024 19:43 by pollipop Investing in Angle in July 2020 and following the company’s progress since then has been for me a valuable lesson.Let it be known that I invested a modest 3k in July 2020, kept faith with the company until the FDA approval milestone, bagged 3k profit and then gave it all back, more or less, as the shares sunk from my 56p entry price over the last 4 years to the current dismal 7p. A small wager and a disappointing loss indeed – I place strict limits on highly speculative shares. I understand a development stage medical technology company needs continual investor support over many years to become a commercial success. It appears Angle has clocked 10 years on its journey to date, has raised £150m capital with £18m remaining. It is also clear from the above synopsis, to me at least, that we face many more years to commercial viability. Therefore, it is understandable that the founder / CEO will do all he can to string investors along. By all accounts he has done a good job in this regard although, with the latest results, I sense he is running out of rope. Whilst company management like to imply that they are just two years away from commercial viability, current realities and recent history suggest otherwise. Thus the key question for investors is are they in a mood to finance a further 5 to 6 plus years of this journey? What do I mean by recent history? Going back through the company reports and presentations, it seems Angle took several wrong turns and/or was forced to abandon things for lack of funding, the Canadian test laboratory and assay development being the most prominent. What is disconcerting for shareholders is the lack of follow up from company management. I list the key items below:- Post FDA opportunities (characterized as: “Enhanced engagement post FDA with discussions initiated with two medtech companies, more than twenty biopharma companies and one Government body”) – a total of 23 potential clients evaporate without a single contract signed and no explanation forthcoming for such an astounding lack of commercial interest. Solaris Health clinical validity study (results expected late 2023) – prostate cancer is one of Angle’s primary target markets but no update for 9 months from management. Breast cancer – despite Parsortix being FDA approved for breast cancer sampling and despite the compelling use case there has been no progress towards commercialization and no explanation from management. Ovarian cancer – if breast cancer use case is clearly NOT compelling why should ovarian cancer use case be? Collaboration with Abbott laboratories for HER2 in breast cancer - evaporated with no explanation from management. Collaboration with Qiagen for ARV7 in prostate cancer - evaporated with no explanation from management. INFORM, EMBER2 and DOMINO clinical studies pivotal to Angle’s commercialization strategy “to generate meaningful clinical data by end of 2023”. No meaningful update re EMBER2 and DOMINO studies nine months after the expected date for headline results, still awaiting results from INFORM, no new dates given in the interim report. So, to repeat, this is going to require new capital, a lot of new capital. New or recent investors tend to be more optimistic; those of us that have been on board for several years ought to be sceptical. |
Posted at 19/9/2024 06:59 by ohwhatfun This isn’t a battle against private investors it’s about challenging Angle apparently inflated or misleading information to protect investors.Who was a leading poster stating a fund raise was coming in June. Fund raises do not happen overnight, they are discussed with the broker and approaches are made to potential backers, it leaks all over the place. If they struggle to get backers, the knowledge web widens swiftly and articles from the usual suspects get published to facilitate a collapse for shorters and force an RNS. The term is bucket shops, if they get involved then everyone in the inside shorting game knows The market makers who will hear about the raise are more than happy to run up the share price during a raise forward selling, shorters involved too closing out their position in the raise. Private investors rave about oversubscribed, yep you can add millions of shares trying to close out forward selling from higher prices So share price behaviours are often a key clue to a raise coming. The market knows how fear of missing out works, up the price and private investors buy, walking straight into a discounted raise. So watch out for those things, it happened pre June raise. A raise that investors were sure wasn’t coming. |
Posted at 13/9/2024 09:43 by radderssandy Yas,Are you referring to the AN interview by Sarah Lowther in June 2022? Which, I think it’s fair to say, was not one of his best interviews. I do, however, think his comments on investors, whilst unwise, have been misconstrued. I have listened to many of AN’s interviews/presentat For the record this is a transcript of what he said. “It is quite important that any investors that join us understand what we're trying to achieve. We're not trying to make a bit of money really quickly and then sell off. It's just we're not interested in that, and we're not really interested in investors who want to think like that. In fact, I made a point of thanking investors generally and I thanked a number of them specifically for their support over six and a half years during our process to get FDA clearance. Because it's not been an easy road for our investors. The stock market can be a bit short term in nature and we are a long term business. So we welcome investors. We really want investors who understand that our aim is to make a difference and improve patient outcomes and recognise that this is a sustained effort over a significant period of time for us to be successful. So we want investors who believe in that and want to be part of it, and we will welcome those investors and we'll provide as much communication and support as we can. Back to the investors. What we don't want, as I said, is day traders and hedge funds and stuff trying to make a bit of a turn. That's just not what we're about at all.” |
Posted at 23/7/2024 07:33 by ohwhatfun Just read the AGM notes Timbo thanks, and replies.Fund raise. No some were not saying trouble fund raising, they said trouble raising the typical required amount £20m. Previous raises have been £20m with more cash in the bank at the time of the raise. Had they raised £20m, as per posts, various new private investors would have bought, others would add. Instead you have a number of investors doubtful of revenue claims, knowing that event triggers negative news, and the miss shortens the time to the next raise. Why it’s difficult to raise currently at prices and amounts is in the notes. Some mention Avacta 50p raise 75p now, it was over £1 shortly before the raise, with posters trashing others who suggested a big discounted raise was coming. Revenue this year HOPE to get 2 more customers this year, what over £2m each against examples of £150k. Not confident or very confident, HOPE. Oversubscribed raise, show me news of raises where they are not oversubscribed over the years. It’s been explained a number of times, fund raises are supposed to be closed circles but are far from it. In the subscribed list for AGL would have been demand to close short positions opened in knowledge of the raise. Just about every raise sees the share price fall below the raise price, yet AGL seem oblivious to this, suggesting incompetence. The loss of bread and butter small company revenue in this sector is evident in other companies, 75%+ revenue drops in some cases, explained as funding drying up. That’s not AGL that’s the sector. AGLs fix was to proactively start chasing big Pharma. All the confidence and loud claims now seems to be based on 2 with HOPE. Hope based on hard-nosed sale tactics. Yeah the deal is you pay for everything, we keep the IP you create and paid for. I fail to see the buyer carrot on a stick there, minnows trying to bully majors. The hope of 2 more customers, needs to be done swiftly to count for revenue this year. It sounds like revenue is going to be missed by some way. That’s not a good advert for new investors to buy now. Some don’t like coin flip investment timing |
Posted at 05/5/2024 09:52 by davidosh For the whole of this long weekend any investor buying a ticket for the *Mello2024* event will be given the bonus of being able to bring a friend or family member completely free of charge. Worth getting a friend to join with you and halving the cost maybe...Will end at market open on Tuesday as it is a bank holiday weekend so plenty of time to connect Mello2024 investor conference takes place on the 22nd and 23rd May Do come and join us....another six companies added to the list today and another six to be announced on Monday. We want to keep this important face to face engagement with companies going and it has been tough since Covid as many directors just want to do webinars as their only token offering to investors. If you want to ask private questions or check out body language it is impossible on webinars and investors need to network with each other too. Please support us and encourage companies/ management teams you are in contact with to come along to Mello2024 in Chiswick on 22nd or 23rd May Mello2024 – Mello Events If you have never been to one of our two day conferences before then clearly you are missing a great opportunity to engage with management teams and also network with hundreds of likeminded investors so we are offering virgin tickets at just £30 for either of the days so that you can see what it is all about.....a big discount from £99.00 and if you do not agree having spent the day with us I will give you an annual pass to our virtual shows on top. I just want investors engaging with all these quality smaller companies. This offer is only if you have never attended before so please be fair to all those who pay much more.... Simply enter the code NEW2MELLO24 BUY NOW: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
